Protagonist can opt out of its co-development deal with Takeda post-NDA filing. This move triggers a $400 million payment and converts the partnership to a high-royalty model (14-29%). This structure allows them to de-risk commercialization while retaining significant financial upside, effectively creating a lucrative licensing deal on demand.

Major firms like Merck employ varied deal structures to build pipelines. Merck's $6.7 billion all-upfront acquisition of Terns for a Phase 1-2 asset contrasts with its Quotient collaboration, which has a small $20 million upfront but $2.2 billion in discovery-stage milestones. This highlights a flexible approach to risk and reward.

Gilead's acquisition of Arcellx includes a CVR, promising an extra $5 per share if the drug anita-cel hits a $6B sales target by 2029. This structure mitigates upfront risk for Gilead while allowing Arcellx shareholders to benefit from future commercial success, aligning incentives post-acquisition.

Beyond funding operations, a strong cash position is a crucial, often unstated, strategic asset for biotechs. It provides significant leverage in partnership discussions with large pharmaceutical companies, allowing smaller firms to reject unfavorable terms and signal they do not need a deal to survive.

Contrary to the focus on large upfront payments, a smarter partnership strategy is to negotiate for a larger share of downstream success through royalties and milestones. This can yield far greater long-term returns if the product succeeds.

According to Kainova's CEO, the primary goal of a new biotech platform's first pharma partnership is not financial. It's to secure a prestigious partner name to validate the technology. This external validation, or "PR value," is more critical early on than maximizing the upfront payment, as it builds credibility for future, more lucrative deals.

Astute biotech leaders leverage the tension between public financing and strategic pharma partnerships. When public markets are down, pursue pharma deals as a better source of capital. Conversely, use the threat of a public offering to negotiate more favorable terms in pharma deals, treating them as interchangeable capital sources.

For pre-revenue biotechs like Voyager, partnering provides non-dilutive capital. More importantly, it de-risks development by sharing costs and leveraging a larger company's resources and expertise. This can increase a drug's probability of success, a crucial factor when most programs fail.

Celcuity began its first-line Phase 3 study before seeing initial pivotal data, a calculated risk. The CEO framed it as a $20 million bet that could accelerate development by a year and add a billion dollars in net present value, making it a highly asymmetric opportunity.